leadf
logo-loader
view4D pharma PLC

4d Pharma acquisition provides for own production facilities

Biotherapeutics firm 4d Pharma PLC has bought a Spanish contract research group, which provides the group with its own production facilities. n.

Pictured - a clinical laboratory...
Alex Stevenson, 4D's chief scientific officer, said: "Over the past 12 months, we have witnessed first-hand the issues of relying on third party providers for the production of our product for clinical and development programmes.”

Biotherapeutics firm 4d Pharma PLC (LON:DDDD) has bought  a Spanish contract research group, which provides the group with its own production facilities.

Biomar, based in north-west Spain, has been an outsourced development partner of the firm since 2014 but now it has bought it for €3 million, payable on completion.

Alex Stevenson, 4D's chief scientific officer, said: "Over the past 12 months, we have witnessed first-hand the issues of relying on third party providers for the production of our product for clinical and development programmes.

"As our pace of development continues, with more of our programmes moving towards the clinic, 4D needs continued access to its own facilities to meet the challenges of our ambitious clinical development programmes, but also in looking forward to our initial production requirements."

Biomar initially focused on research into marine microorganisms, but in 2001 began to expand its technologies into microbial fermentation, providing contract services in this field and expanding its production capabilities up to 3,000 litres in 2010.

Shares eased 1.54% to 960p.

Quick facts: 4D pharma PLC

Price: 136 GBX

LSE:DDDD
Market: LSE
Market Cap: £178.84 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of 4D pharma PLC named herein, including the promotion by the Company of 4D pharma PLC in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

2 min read